10-K: Vystar Corporation Files Annual Report for Fiscal Year 2025

Vystar Corporation filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, detailing financial performance, business operations, and risk factors.

Summary

• Vystar Corporation reported a significant decrease in revenue for the fiscal year ended December 31, 2025, with consolidated revenues at $54,821 compared to $135,969 in 2024, a decline of 59.7%.
• Operating expenses also decreased by 31.2% to $1,092,355 in 2025 from $1,587,220 in 2024, primarily due to reduced consulting and professional fees.
• The company incurred a net loss of $1,531,850 for the year, a substantial decrease from a net income of $2,520,312 in the prior year, which included significant income from discontinued operations.
• Vystar continues to face substantial doubt regarding its ability to continue as a going concern, with cash on hand at $4,454 and a working capital deficit of $6,614,169 as of December 31, 2025.
• The company plans to finance future operations through cash on hand, increased revenue from RxAir products and Vytex license fees, and potential stock issuances.
• The legal proceedings with EMA Financial were largely resolved in Vystar's favor, with a final award of $497,439.58 in attorneys' fees and costs granted in December 2025.
• The company is actively pursuing strategic initiatives, including a binding letter of intent to acquire 50% of Capital R3alm, Inc., a Web3 financial ecosystem developer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant revenue decline, widening net loss, and ongoing going concern issues, despite some positive strategic developments and legal resolutions.

Positives

• Successful resolution of the EMA Financial lawsuit, resulting in an award of $497,439.58 in attorneys' fees and costs.
• Reduction in operating expenses by 31.2% to $1,092,355, driven by decreased consulting and professional fees.
• Advancement in strategic partnerships with the signing of a binding letter of intent to acquire 50% of Capital R3alm, Inc., indicating a move into the Web3 financial ecosystem.
• Continued development and testing of new RxAir product prototypes, including the RX800 and RX300 (to be renamed RX600).
• The Vytex brand is being expanded into the consumer arena with an introduction into the bedding category.

Negatives

• Significant revenue decline of 59.7% to $54,821 in 2025 from $135,969 in 2024.
• Net loss of $1,531,850 for the year ended December 31, 2025, compared to a net income of $2,520,312 in 2024.
• Substantial doubt about the company's ability to continue as a going concern, with only $4,454 in cash and a working capital deficit of $6,614,169.
• Accumulated deficit increased to $61,384,883 as of December 31, 2025.
• The RX3000 Commercial FDA cleared Class II Air Purifier is currently not in production.
• The company expects production delays for FEC/Hughes devices until late 2027 due to tariffs and cash flow issues.

Risks

• The company presently does not generate the cash needed to finance its current and anticipated operations and may not be able to achieve or maintain profitability.
• The company's financial success is dependent on its business concept, management's ability to execute its plan, and its ability to raise additional capital.
• The RxAir business faces significant competition from multinational and regional manufacturers.
• The Vytex business is dependent on market demand and acceptance of its Natural Rubber Latex technology.
• Fluctuations in commodity prices for Natural Rubber Latex (NRL) can adversely affect profits.
• Cybersecurity risks could adversely affect the company's operating effectiveness and results.
• The utilization of tax losses could be substantially limited if the company experiences an ownership change.
• The company does not expect to declare any cash dividends in the foreseeable future.

Future Outlook

The company plans to finance future operations using cash on hand, increased revenue from RxAir air purifier sales and Vytex license fees, and stock issuances. Management anticipates that future expenditures will depend on the rate of product introduction, licensing, patent costs, market acceptance, and broader economic factors. There is substantial doubt about the company's ability to continue as a going concern, and failure to achieve projected revenues or obtain additional financing could lead to significant curtailment of operations or bankruptcy.

Management Comments

• The Company will aggressively review its pricing and sales strategies in 2026.
• Management plans to finance future operations using cash on hand, as well as increased revenue from RxAir air purifier sales and Vytex license fees, that now also include the Companys association with foam cores made from Vytex used in mattresses, mattress toppers and pillows.
• Management expects to strengthen internal control during 2026 by developing stronger business and financial processes for accounting for transactions such as stock issuances, which will enhance internal control for the Company.

Industry Context

StockSavvy.ai notes that Vystar's performance in the air purification and natural rubber latex markets is impacted by intense competition and evolving consumer demand. The company's strategic pivot towards Web3 with the Capital R3alm acquisition signals an attempt to diversify and tap into emerging technological trends, though significant financial challenges remain.

Comparison to Industry Standards

• The air purification market is highly fragmented, with Vystar competing against numerous companies on price, quality, innovation, reputation, distribution, and promotion.
• In the natural rubber latex market, synthetic alternatives have captured a significant portion of the market, though NRL remains dominant in specific applications like medical gloves.
• The company's Vytex NRL technology aims to reduce protein levels, a key differentiator in a market where latex allergies are a concern, though FDA approvals for new claims remain a challenge.
• The company's financial performance, particularly its revenue decline and going concern issues, contrasts sharply with established players in the chemical and consumer goods sectors.

Corporate Governance

Legal Proceedings

• The lawsuit filed by EMA Financial, Inc. was largely resolved in Vystar's favor, with the District Court awarding Vystar $497,439.58 in attorneys' fees and costs on December 22, 2025. EMA Financial filed a further appeal on January 21, 2026.

Related Party Transactions

• Employment Agreement with Jamie Rotman (CEO) for annual compensation of $180,000, payable in Series C Preferred Stock or common stock at a 50% discount, plus a $25,000 signing bonus.
• Consulting agreement with Blue Oar Consulting, Inc. (owned by Gregory Rotman, brother of CEO Jamie Rotman) for monthly fees of $15,000 cash for expenses and $12,500 in shares.
• Dr. Bryan Stone (Director) receives a $25 per unit commission for RxAir units sold to a specific customer.
• Steven Rotman (former CEO) had an employment agreement with annual compensation of $125,000 cash, monthly shares at a 50% discount, and monthly expenses.
• Various advances and stock subscription payables exist between the company and related parties, including Jamie Rotman, Gregory Rotman (Blue Oar), and Steven Rotman.

Stakeholder Impact

• Shareholders: Continued uncertainty regarding the company's going concern status and potential for dilution from future stock issuances. The lack of dividends means returns are solely dependent on stock price appreciation.
• Employees: The company's financial instability poses a risk to job security. Management is focused on strengthening internal controls.
• Creditors/Noteholders: The company's ability to meet its debt obligations is a concern given its cash position and ongoing losses. Several notes are in default or have had maturity dates extended.
• Suppliers: Potential for payment delays or disruptions due to the company's liquidity challenges.

Next Steps

• Aggressively review pricing and sales strategies in 2026.
• Continue development and testing of new RxAir product prototypes.
• Pursue the acquisition of 50% of Capital R3alm, Inc. and integration of its Web3 financial ecosystem.
• Strengthen internal controls during 2026.
• Seek to achieve projected revenue levels in 2026 and beyond.
• Obtain alternate additional financing of equity or debt if necessary.

Key Dates

Recommendation

While Vystar has resolved a significant legal matter and is pursuing strategic diversification into Web3, the company's severe financial distress, declining revenues, and ongoing going concern issues present substantial risks. The potential for future capital raises and the success of the Capital R3alm acquisition are key factors, but the immediate outlook remains highly uncertain, warranting a cautious 'hold' stance.

Keywords

Vystar Corporation, Form 10-K, Annual Report, Vytex, RxAir, Natural Rubber Latex, Air Purification, Financial Results